Literature DB >> 2435045

5-Fluorouracil (5-Fu) in the treatment of prostatic hyperplasia.

X Y Wei, X M Zhou.   

Abstract

A prospective study of 5-Fu in the treatment of prostatic hyperplasia was commenced in 1981. The short term results were fair in 70% of 43 patients. Atrophy of the glandular tissue could be observed on histopathologic examination. The study showed that the larger the glandular component the better was the therapeutic effect. If abundant fibromuscular tissue was present in the gland the treatment was unsatisfactory. Abnormal anatomy of the bladder neck, represented a contraindication to medical treatment.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 2435045     DOI： 10.1007/bf00256333

Source DB:  PubMed          Journal:  Urol Res        ISSN： 0300-5623


  5 in total

Review 1.  Mechanism of action of the sex steroid hormones (first of three parts).

Authors:  L Chan; B W O'Malley
Journal:  N Engl J Med       Date:  1976-06-10       Impact factor: 91.245

2.  [Effect of estradiol, diethylstilbestrol, progesterone, and gestonorone capronate (depostat) on the 5 alpha-reductase kinetics in benign prostatic hypertrophy (BPH) (author's transl)].

Authors:  J E Altwein; A Rubin; K Klose; P Knapstein; F Orestano
Journal:  Urologe A       Date:  1974-01       Impact factor: 0.639

3.  Cyproterone acetate in the treatment of advanced carcinoma of the prostate.

Authors:  R B Smith; P C Walsh; W E Goodwin
Journal:  J Urol       Date:  1973-07       Impact factor: 7.450

4.  Antiandrogenic effect of spironolactone in rats.

Authors:  G T Basinger; R F Gittes
Journal:  J Urol       Date:  1974-01       Impact factor: 7.450

5.  Altered blood androgens in elderly men with prostate hyperplasia.

Authors:  R Horton; P Hsieh; J Barberia; L Pages; M Cosgrove
Journal:  J Clin Endocrinol Metab       Date:  1975-10       Impact factor: 5.958
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.